Melbourne, Australia , 20 June 2012 – A new therapy to treat a common hospital superbug* infection Clostridium difficile, will soon be available to Australian & New Zealand patients. Melbourne biopharmaceutical company Specialised Therapeutics Australia Pty, Ltd. (STA) has entered into an exclusive distribution & license agreement with US based Optimer Pharmaceuticals, Inc. (Optimer) to develop and
